Eton Pharmaceuticals, Inc. ETON 深 沪
等待开盘 04-02 09:30:00 美东时间
25.36
+0.680
+2.76%
华盛通- 最 高25.99
- 今 开25.06
- 成交量 72.38万股
- 最 低 24.53
- 昨 收 24.68
- 总市值 6.92亿
- 52周最高 25.99
- 市盈率 静 --
- 换手率 2.65%
- 52周最低 12.25
- 委 比 33.33%
- 总股本 2728.45万
- 历史最高 25.99
- 量 比 1.47
- 振 幅 5.92%
- 历史最低 1.95
- 每 手 1
- 风险率 2.30%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多The Insider Report: Markets Wade into Geopolitical Abyss
Market Overview Stocks got hit hard last week as the market is no longer buying...
03-30 01:10
美股大行评级 | 小摩、瑞穗等下调阿里目标价最低至164美元；达登饭店、联邦快递、林肯教育服务、Planet Labs等获多家大行上调目标价
今日重点评级关注：瑞穗：维持RELMADA THERAPEUTICS"跑赢大市"评级，目标价从10美元升至19美元；奥本海默：维持Pelthos Therapeutics"跑赢大市"评级，目标价从60美元升至62美元
03-23 13:53
Craig-Hallum Maintains Buy on Eton Pharmaceuticals, Raises Price Target to $35
Craig-Hallum analyst Chase Knickerbocker maintains Eton Pharmaceuticals (NASDAQ:ETON) with a Buy and raises the price target from $30 to $35.
03-21 01:15
Eton Pharmaceuticals Q4 Adj. EPS $0.19 Beats $0.09 Estimate, Sales $21.281M Beat $20.579M Estimate
Eton Pharmaceuticals (NASDAQ:ETON) reported quarterly earnings of $0.19 per share which beat the analyst consensus estimate of $0.09 by 111.11 percent. This is a 1050 percent increase over losses of $(0.02) per share
03-20 04:17
Earnings Scheduled For March 19, 2026
Companies Reporting Before The Bell • Neuraxis (AMEX:NRXS) is projected to repo...
03-19 19:11
美股大行评级 | 绩后暴跌超22%，MongoDB遭14家大行集团下调目标价；挪威邮轮、阿莎娜、Quantum Computing等也遭大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持NRX Pharmaceuticals"买入"评级，目标价从40美元升至45美元；RBC Capital：维持NUVATION BIO"跑赢大市"评级，目标价从12美元升至13美元
03-04 10:22
美股大行评级 | 花旗：维持康菲石油"买入"评级！目标价从125美元升至135美元
今日重点评级关注：HC Wainwright & Co.：维持Helus Pharma"买入"评级，目标价从55美元升至95美元；HC Wainwright & Co.：维持Compass Pathways"买入"评级，目标价从40美元升至70美元
03-03 20:22
Eton Pharmaceuticals Announces FDA Approval Of NDA For DESMODA Oral Solution For Management Of Central Diabetes Insipidus
DESMODA is the first and only FDA-approved desmopressin oral solutionCommercial launch expected on March 9thDESMODA eliminates tablet splitting and crushing, enabling precise, individualized dosing for patients of all
02-26 03:03
Eton Pharma Announces Licensing Of U.S. Marketing Rights To Ultra-Rare Disease Product Candidate; Product Is Currently Under Review With FDA; Potential Approval And Launch Mid-2026
Eton Pharmaceuticals, Inc ("Eton" or "the Company") (NASDAQ:ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the
02-02 19:51
Eton Pharmaceuticals Joins Piper Sandler Healthcare Conference
The latest announcement is out from Eton Pharmaceuticals ( ($ETON) ). On Decemb...
2025-12-04 20:58
